{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:48:45Z","timestamp":1760384925346},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.ijantimicag.2008.12.007","type":"journal-article","created":{"date-parts":[[2009,2,7]],"date-time":"2009-02-07T10:59:28Z","timestamp":1234004368000},"page":"543-548","source":"Crossref","is-referenced-by-count":52,"title":["Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin\u00ae Outcomes Registry and Experience (CORE)"],"prefix":"10.1016","volume":"33","author":[{"given":"John F.","family":"Mohr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence V.","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Yankelev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Lamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2008.12.007_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.diagmicrobio.2007.06.001","article-title":"Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries","volume":"59","author":"Jones","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diagmicrobio.2004.05.003","article-title":"Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997\u20132002)","volume":"50","author":"Biedenbach","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.diagmicrobio.2006.05.009","article-title":"Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998\u20132004)","volume":"57","author":"Moet","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1476-0711-3-14","article-title":"Emerging resistance among bacterial pathogens in the intensive care unit\u2014a European and North American Surveillance study (2000\u20132002)","volume":"3","author":"Jones","year":"2004","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/430909","article-title":"Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis","volume":"41","author":"DiazGranados","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib7","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1128\/AAC.45.6.1919-1922.2001","article-title":"In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers","volume":"45","author":"Barry","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin\u2013dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib9","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1128\/AAC.47.8.2538-2544.2003","article-title":"Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus","volume":"47","author":"Silverman","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib10","unstructured":"Cubicin [package insert]. Lexington, MA: Cubist Pharmaceuticals, Inc.; 2007."},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jac\/dkg288","article-title":"The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species","volume":"52","author":"Richter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jhm.236","article-title":"Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin","volume":"2","author":"Jenkins","year":"2007","journal-title":"J Hosp Med"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1592\/phco.27.6.927","article-title":"A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin","volume":"27","author":"Barber","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jinf.2006.11.007","article-title":"Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients","volume":"54","author":"Poutsiaka","year":"2007","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/00365540500434687","article-title":"Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia","volume":"38","author":"Kvirikadze","year":"2006","journal-title":"Scand J Infect Dis"},{"issue":"10 Suppl. 1","key":"10.1016\/j.ijantimicag.2008.12.007_bib16","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.amjmed.2007.07.008","article-title":"Cubicin Outcomes Registry and Experience (CORE) methodology","volume":"120","author":"Rolston","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1469-0691.2006.01550.x","article-title":"Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002\u20132004)","volume":"12","author":"Sader","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2334-7-29","article-title":"Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)","volume":"7","author":"Sader","year":"2007","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.diagmicrobio.2008.01.016","article-title":"Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006)","volume":"61","author":"Castanheira","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2006.10.007","article-title":"Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002\u20132005)","volume":"57","author":"Pfaller","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib21","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1128\/AAC.31.11.1779","article-title":"Activity of LY146032 against enterococci with and without high-level aminoglycoside resistance, including two penicillinase-producing strains","volume":"31","author":"Wanger","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijantimicag.2006.07.017","article-title":"In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin\/dalfopristin","volume":"28","author":"Anastasiou","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib23","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1128\/AAC.47.5.1598-1603.2003","article-title":"Daptomycin dose\u2013effect relationship against resistant gram-positive organisms","volume":"47","author":"Cha","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib24","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/AAC.49.12.5046-5050.2005","article-title":"Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm","volume":"49","author":"Raad","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/AAC.33.7.1019","article-title":"Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin","volume":"33","author":"Hindes","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib26","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/jac\/dkl406","article-title":"Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci","volume":"58","author":"Vouillamoz","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib27","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1128\/AAC.47.11.3561-3566.2003","article-title":"Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection","volume":"47","author":"Alder","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1592\/phco.26.3.347","article-title":"Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients","volume":"26","author":"Segreti","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib29","unstructured":"Gallagher JC, Perez ME, Rose CM, Abrardo L, Marino E, Walker M. Daptomycin monotherapy in the treatment of vancomycin-resistant enterococcal bacteraemia. In: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 19-22 April 2008; Barcelona, Spain. Abstract R 2353. http:\/\/www.akm.ch\/eccmid2008 [accessed 19 May 2008]."},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib30","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.bbmt.2007.01.078","article-title":"Colonization, bloodstream infection, and mortality caused by vancomycin-resistant Enterococcus early after allogeneic hematopoietic stem cell transplant","volume":"13","author":"Weinstock","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib31","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.49.4.1664-1665.2005","article-title":"Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy","volume":"49","author":"Lewis","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib32","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1086\/522656","article-title":"Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster","volume":"45","author":"Arias","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.007_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1086\/523588","article-title":"Impact of the more-potent antibiotics quinupristin\u2013dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia","volume":"46","author":"Erlandson","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"10 Suppl. 1","key":"10.1016\/j.ijantimicag.2008.12.007_bib34","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.amjmed.2007.07.012","article-title":"Daptomycin in the treatment of bacteremia","volume":"120","author":"Sakoulas","year":"2007","journal-title":"Am J Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485790900017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485790900017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T01:28:15Z","timestamp":1545442095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485790900017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S092485790900017X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.12.007","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}